We are live on ! Find out more
ELI

ELITE PHARMACEUTICAL
ELI

Delisted

ELI was delisted on the 20th of May, 2009.

Back to rankings

2 hedge funds and large institutions have $38.4K invested in ELITE PHARMACEUTICAL in 2013 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

110% more capital invested

Capital invested by funds: $18.3K → $38.4K (+$20.1K)

0% more funds holding

Funds holding: 2 → 2 (0)

Holders
2
Holders Change
–
Holders Change %
0%
% of All Funds
0.06%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
1
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
GA
Geneva Advisors
Illinois
+$6.2K

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
GA
1
Geneva Advisors
Illinois
$31K +$6.2K +50,000 +25%
JAFL
2
Jay A. Fishman Ltd
Michigan
$7.43K – – –

ELI Hedge Fund Activity: Q3 2013 in Review

2 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in ELITE PHARMACEUTICAL (ELI) for Q3 2013, worth a combined $38.4K — up 110% from $18.3K a quarter earlier.

Fund positioning in ELI was balanced in Q3 2013: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 0 trimmed.

The largest buyer was Geneva Advisors, adding an estimated $6.2K.

  • 2 institutional investors held ELITE PHARMACEUTICAL (ELI) as of Q3 2013, unchanged from Q2 2013.
  • Funds reported $38.4K of ELITE PHARMACEUTICAL stock for Q3 2013, up 110% quarter-over-quarter.
  • 0 funds opened new ELITE PHARMACEUTICAL positions in Q3 2013 and 0 closed out.
  • The largest ELITE PHARMACEUTICAL buyer in Q3 2013 was Geneva Advisors, an estimated $6.2K added.

Based on aggregated 13F filings for Q3 2013.